Celgene's anticancer drug Abraxane (Paclitaxel) is expected to cut the drug price by 3.6% next month as the scope of use is expanded. Janssen Korea's prostate cancer treatment Zytiga 500mg (Abiraterone Acetate) is subject to a 5% cut rate due to an additional indication, and advance drug price cuts are being promoted.

Takeda Pharmaceutical Korea's lymphoma treatment Adcetris (Brentuximab Vedotin) and metastatic non-small cell lung cancer treatment Alunbrig (Brigatinib) dropped 1.4% and 1.5%, respectively. The MOHW is promoting the revision of the drug reimbursement list as of April 1.

◆Preliminary drug price reduction due to expansion of the scope of use = The government will lower th